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Background: Circulating cell-free fetal DNA has enabled non-invasive prenatal fetal aneuploidy testing without
direct discrimination of the maternal and fetal DNA. Testing may be improved by specifically enriching the sample
material for fetal DNA. DNA methylation may allow for such a separation of DNA; however, this depends on knowledge
of the methylomes of circulating cell-free DNA and its cellular contributors.
Results: We perform whole genome bisulfite sequencing on a set of unmatched samples including circulating cell-free
DNA from non-pregnant and pregnant female donors and genomic DNA from maternal buffy coat and placenta
samples. We find CpG cytosines within longer fragments are more likely to be methylated. Comparison of the
methylomes of placenta and non-pregnant circulating cell-free DNA reveal many of the 51,259 identified differentially
methylated regions are located in domains exhibiting consistent placenta hypomethylation across millions of consecutive
bases. We find these placenta hypomethylated domains are consistently located within regions exhibiting low CpG and
gene density. Differentially methylated regions identified when comparing placenta to non-pregnant circulating cell-free
DNA are recapitulated in pregnant circulating cell-free DNA, confirming the ability to detect differential methylation in
circulating cell-free DNA mixtures.
Conclusions: We generate methylome maps for four sample types at single-base resolution, identify a link between
DNA methylation and fragment length in circulating cell-free DNA, identify differentially methylated regions between
sample groups, and uncover the presence of megabase-size placenta hypomethylated domains.Background
The field of non-invasive prenatal testing was enabled by
the discovery that circulating cell free (ccf) fetal DNA is
present pregnant female plasma [1]. It does, however,
only present the minority species of DNA in total ccf
DNA obtained from pregnant women. This mixture
consists of DNA inherently present in the plasma of
non-pregnant females, thought to primarily be derived
from maternal hematopoietic cells, supplemented with a
minority fraction of fetal DNA coming from the placenta
[2-5]. Since these nucleic acids are distinct, they can be
differentiated through a number of genomic markers
including single nucleotide changes, haplotypes, or copy
number variants. In addition, DNA methylation can* Correspondence: tjensen@sequenom.com
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unless otherwise stated.serve as a distinguishing feature and has thus been evalu-
ated for fetal DNA enrichment [6-9]; however, complete
analysis requires an in-depth knowledge of the genome-
wide DNA methylation patterns in ccf DNA isolated from
pregnant plasma as well as its primary non-cellular and
cellular contributors.
DNA methylation participates in numerous develop-
mental processes including X chromosome inactivation,
genomic imprinting, and cellular differentiation [10-13].
Differences in DNA methylation patterns are cell type
specific and, in concert with histone tail modifications
and other epigenetic alterations, cooperate to modulate
chromatin structure [14-17]. While the majority of pre-
vious epigenetic studies have been performed upon only
a portion of the genome [6,14,18-20], recent research
from the ENCODE project indicates that up to 80% of
the human genome may be functional, highlighting theThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tirety [21]. Utilizing sequencing techniques that permit
complete methylome analysis, a number of studies have
described genome-wide methylation profiles of normal
and cancer samples [22-30]; however, high resolution
methylation maps of complex biological specimens in-
cluding ccf DNA only recently been described [31].
We performed whole genome bisulfite sequencing
(WGBS) [22,25-27] to characterize the methylome of ccf
DNA from eight non-pregnant and seven pregnant fe-
male donors. In addition, seven genomic DNA samples
isolated from maternal buffy coat and five placenta sam-
ples were sequenced at single base resolution. This pro-
duced DNA methylome maps for each sample type. The
present study provides single-base resolution methy-
lomes of ccf DNA, demonstrates a link between local
DNA methylation levels and ccf DNA fragment size, and
shows large, continuous regions of hypomethylation in
the placenta (placenta hypomethlated domains (PHDs)),
an epigenetic phenomenon, until recently, only de-
scribed in tumor samples [24,30,32-35].
Results
Single base resolution methylome maps of ccf DNA iso-
lated from the plasma of eight non-pregnant female do-
nors were produced using WGBS. We generated 269 to
551 million paired monoclonal reads per sample, enabling
>10x coverage of 74% to 92% of the approximately 28 mil-
lion genomic CpG sites (Additional file 1: Figure S1a).
Cytosine methylation was evaluated in each of the previ-
ously identified genomic contexts (CpG, CHG, and CHH)
[26]. Consistent with previous studies on differentiated
cell types [36], almost all cytosine methylation occurred in
the CpG context with 74.5% to 75.3% of all CpG cytosines
being methylated; methylation in each of the other con-
texts was minimal (<0.25%; Additional file 1: Figure S1b).
These data created eight comprehensive genome-wide
CpG cytosine methylation maps of ccf DNA which can
serve as a foundation for subsequent comparisons within
this study and beyond (Additional file 1: Figure S1c).
Previous work has indicated that the predominant
contributor to non-pregnant ccf DNA are cells of
hematopoietic origin [4]. This led us to perform WGBS
on buffy coat cells obtained from seven distinct pregnant
female donors (Additional file 2: Figure S2). Methylation
levels at 37,775 CpG sites were confirmed by MassAR-
RAY in an independent sample cohort of eight buffy
coat samples (Pearson correlation = 0.953; Additional file
1: Figure S3). Nearly all CpG sites in buffy coat showed
either low (9.7%; defined as less than 20% mean methy-
lation across all buffy coat samples) or high (79.8%; de-
fined as greater than 75% mean methylation across all
buffy coat samples) levels of methylation (Figure 1a),
similar to the distribution in non-pregnant ccf DNA.Next, the link between histone tail modifications and
DNA methylation was examined. Publically available
PBMC ChIP-Seq data from the ENCODE project were
used to identify regions enriched for four distinct histone
H3 modifications. Since the methylome of non-pregnant
ccf DNA closely resembled that of buffy coat (PBMC), the
level of CpG methylation in non-pregnant ccf DNA was
then examined within these regions (Figure 1b). In regions
enriched for H3K4me3, 89.9% of cytosines showed less
than 20% methylation while only 5.2% of unenriched sites
were similarly unmethylated. Conversely, 84.9% of CpG
sites were methylated (>75%) in H3K9me3 enriched regions
compared to 76.3% in unenriched regions. Distinct differ-
ences were also observed when comparing H3K4me1 and
H3K27me3 enriched regions to corresponding unenriched
CpG sites. Taken together, these data suggest a link be-
tween particular histone marks and CpG methylation in
buffy coat. Comparison of the methylomes of buffy coat
and non-pregnant ccf DNA indicated high similarity
(Pearson correlation = 0.954; Additional file 1: Figure S4);
however, we detected 152 differentially methylated regions
(DMRs) (139 more methylated in buffy coat), suggesting
there are additional sources of cell free DNA distinct from
buffy coat present in circulation. These data link histone
modifications to CpG methylation in buffy coat and sug-
gest that the majority of ccf DNA is derived from the
hematopoietic compartment with minimal contributions
from alternative tissues.
Since the fetal portion of ccf DNA in pregnant plasma
is derived from the placenta [2-5], WGBS of five placenta
samples was performed to identify of placenta specific
DMRs (Additional file 2: Figure S2). Methylation levels of
37,775 CpG sites were also measured using MassARRAY
in a separate eight sample cohort and showed high con-
cordance (Pearson correlation = 0.897; Additional file 1:
Figure S5). Comparison of the distribution of methylation
in placenta to the distribution in non-pregnant ccf DNA
or buffy coat revealed a significant difference (P <2.2e-16;
Kolmogorov-Smirnov Test). While only 15.5% and 10.5%
of CpG sites exhibited intermediate methylation (20% to
75% mean methylation) in non-pregnant ccf DNA and
buffy coat, respectively, 46.6% of CpG sites showed
intermediate methylation in placenta tissue (Figure 1a).
Comparison of CpG sites between placenta and buffy
coat revealed that the majority of the intermediate
methylated regions in placenta were highly methylated
in both non-pregnant ccf DNA and buffy coat (Additional
file 1: Figure S6 and Figure S7). CpG methylation was
compared to gene expression determined by microarray
analysis on an independent cohort of eight placenta sam-
ples. Transcription start sites (TSS) were generally
unmethylated independent of gene expression level, while
promoter and intragenic regions were linked to gene ex-
pression (Additional file 1: Figure S8).
Figure 1 Methylation patterns in buffy coat, placenta, and non-pregnant ccf DNA. (a) The distribution of mean CpG methylation for each sample
type (non-pregnant ccf DNA, maternal buffy coat, and placenta). The y-axis represents the relative proportion of all evaluated CpG dinucleotides
exhibiting a particular level of CpG methylation. The histogram bins each have a width of 1%. (b) CpG methylation of non-pregnant ccf DNA
samples was assessed in ENCODE-defined enriched regions for H3K4me1, H3K4me3, H3K9me3, and H3K27me3. Unenriched data were generated
by a random sampling of the same number of CpG sites as used for enrichment, but located elsewhere in the genome. The width of each violin
plot is representative of data density at a given CpG methylation level. (c) The number of DMRs more methylated in placenta (red) and
non-pregnant (NP) ccf DNA (blue).
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the aforementioned sample types was then analyzed. We
identified 51,259 DMRs between placenta and non-
pregnant ccf DNA, of which 89.5% were more methyl-
ated in ccf DNA, consistent with the observed distribu-
tion differences (Figure 1c; Additional file 1: Figure S9).
We assayed 243 of the putative DMRs in an independent
sample set of six placenta samples and eight non-
pregnant ccf DNA samples using MassARRAY and
98.8% (240/243; Additional file 1: Figure S10) were con-
firmed (P <0.05; Wilcox Rank Sum). Interestingly, these
DMRs overlapped with CpG islands in only 7.9% of
cases and frequently occurred within intragenic and
intergenic regions (Additional file 1: Figure S11). This
may be due to the observed low CpG methylation levels
within CpG islands in non-pregnant ccf DNA, whereas
other genomic regions, including introns and exons,
were largely methylated in non-pregnant ccf DNA andhypomethylated in placenta (Additional file 1: Figure S12).
In addition, we identified 105,874 DMRs between placenta
and buffy coat with a similar over-representation (94.7%)
of buffy coat specific methylated regions (Additional file 1:
Figure S13 and Figure S14). The majority (93.6%) of
DMRs identified between ccf DNA and placenta were
also identified as DMRs between placenta and buffy coat
(Additional file 1: Figure S15). Comparison of methyla-
tion between buffy coat and placenta in the context of
ENCODE defined histone modifications revealed an in-
teresting pattern. Little difference in methylation is ob-
served within H3K4me3 regions while a dramatic
difference occurs in H3K9me3 and H3K27me3 enriched
regions (Additional file 1: Figure S16). Regions enriched
for H3K4me1 show a generalized decrease in DNA
methylation levels in placenta tissue relative to ccf DNA
from non-pregnant plasma (Additional file 1: Figure
S16). These differences may indicate differential histone
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buffy coat or differences in the correlation between
these marks in the placenta. These data provide a
genome-wide map of placenta specific DMRs when
compared to either non-pregnant ccf DNA or buffy
coat.
Examination of the genomic distribution of differential
methylation uncovered large contiguous genomic re-
gions with significant placental hypomethylation relative
to non-pregnant ccf DNA. We termed these regions
PHDs and found that these domains overlapped with a
substantial portion (29.9%) of all autosomal hypomethy-
lated DMRs. PHDs were characterized by a number of
distinguishing characteristics. First, they were typically
located in regions of low CpG and gene density (gene
deserts). Second, these regions often exhibited highFigure 2 Identification of placenta hypomethylated domains (PHDs). (a) M
non-pregnant ccf DNA (NP ccf DNA) and placenta shown. CpG sites (blue) an
methylation level by CpG density at 50 kbp bin level. Values on the x-axis rep
indicate the number of genomic bins analyzed. (c) Differential methylation be
at 50 kbp bin level. A negative value on the y-axis is indicative of placenta hylevels of DNA methylation in ccf DNA from non-
pregnant plasma (mean methylation 74.2%) while placenta
tissue showed a considerably lower level of methylation
(mean methylation 49.9%). Using a window size of 50 kbp,
we detected PHDs on each autosome that covered as
many as approximately 14 million bases. Figure 2a shows
a number of these regions located on chromosome 16
with particular focus upon a 7.5 Mbp PHD located on
chromosome 16q. Since the presence of a PHD was
consistently observed in regions of low CpG density, the
link between CpG density and methylation levels was
further examined. Indeed, the magnitude of placenta hy-
pomethylation in low CpG density regions far surpasses
that observed in more dense regions (Figure 2b). A
similar pattern is seen when comparing CpG methyla-
tion to gene density (Additional file 1: Figure S17).ean methylation per 50 kbp genomic bin on chromosome 16 with
d genes (orange) were summed per 50kbp genomic bin. (b) Genomic
resent the number of CpG sites per 50 kbp bin. Numbers along the top
tween placenta and non-pregnant plasma as a function of CpG density
pomethylation. The red line corresponds to a loess smoothed fit.
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positively linked to the local CpG density (Figure 2c).
These data identify large genomic regions which are
consistently hypomethylated in the placenta and link
these regions to low CpG and gene density. While add-
itional work is needed to further characterize PHDs,
these characteristics perhaps underscore a lack of het-
erochromatin formation during early placenta develop-
ment or allele specific methylation of regions with low
CpG density in the placenta [37].
We measured the methylome of ccf DNA derived
from the plasma of seven pregnant female donors to see
if we could detect the DMRs identified between placenta
and non-pregnant ccf DNA (Additional file 2: Figure
S2). Overall methylation levels in pregnant and non-
pregnant ccf DNA were similar for non-CpG cytosines
(<0.25%); however, overall methylation within a CpG
context was significantly reduced from a range ofFigure 3 Methylome of ccf DNA isolated from pregnant plasma. (a) Cytosi
and CHH contexts are shown. P values were calculated using a Wilcox rank
hypermethylated in placenta tissue relative to non-pregnant ccf DNA. The
methylation level. (c) Methylation of all cytosines located within the DMRs
The y-axis (density) is the defined as the proportion of CpG sites at a given74.5% to 75.3% to a range of 71.0% to 74.0% (P = 3e-04,
Wilcoxon rank-sum; Figure 3a). Since ccf DNA from
pregnant plasma is comprised of maternal and fetal ccf
DNA, methylation patterns should be a composite of
non-pregnant ccf DNA and placenta tissue. To address
this, we evaluated the mean methylation level of each
CpG site within DMRs identified between non-pregnant
ccf DNA and placenta. CpG sites within identified DMRs
exhibited significantly (P <2e-16; Wilcoxon rank-sum)
different methylation levels in pregnant ccf DNA rela-
tive to non-pregnant ccf DNA (Figures 3b, c; Additional
file 1: Figure S18 and Figure S19). Hierarchical cluster-
ing confirmed these results by clustering pregnant and
non-pregnant ccf DNA samples as single branches on a
dendrogram (Additional file 1: Figure S20). Overall,
these data confirm the differential methylation identi-
fied when comparing non-pregnant ccf DNA and pla-
centa tissue.ne methylation in non-pregnant and pregnant ccf DNA for CpG, CHG,
sum test. (b) Methylation of all cytosines located within the DMRs
y-axis (density) is the defined as the proportion of CpG sites at a given
hypermethylated in non-pregnant ccf DNA relative to placenta tissue.
methylation level.
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shorter than its maternal counterpart [38-40]. Since hy-
pomethylation is linked to an open chromatin structure
and thus may exhibit an increased accessibility to native
endonucleases during apoptosis [41], we assessed the re-
lationship between CpG methylation and ccf DNA
length in non-pregnant plasma to determine if this con-
tributes to the observed size difference. In each of the
samples analyzed, the most prominent length was
168 bp, similar to previous reports (Figure 4a) [38]. After
accounting for the differences in the number of analyzed
bases for each size fraction, we found that CpG cytosines
within longer fragments (>200 bp) were on average 12.3-
fold more likely to be methylated (Figure 4b). Interest-
ingly, a similar pattern was also found for cytosines in
the CHG (31.5-fold) and CHH (95.5-fold) contexts, al-
though their overall occurrence was much lower than
methylated CpG cytosines. A similar relationship be-
tween CpG methylation likelihood and fragment length
was also observed in ccf DNA from the plasma of preg-
nant women but was not observed in the manually
sheared buffy coat and placenta samples (Additional file
1: Figure S21), consistent with this relationship being the
result of biological DNA fragmentation. We performedFigure 4 Linkage between fragment size and local DNA methylation in no
WGBS. Each line represents an individual ccf sample. Loss of representation
to alignment. (b) Ratio of methylated CpG, CHG, and CHH cytosines within
fragments (<200 bp) after scaling for number of cytosines measured. Each
fraction (black) and methylated fraction (gray) using MCIp-Seq. Each line re
distribution of fragment size for each fraction.methyl-CpG immunoprecipitation (MCIp)-Seq on an in-
dependent set of two non-pregnant ccf DNA samples to
confirm the observed size differences for CpG cytosines.
MCIp enables the separation and collection of both the
unmethylated and methylated fractions of a sample. Se-
quencing both fractions from each sample revealed a
distinct size difference with the most striking difference
between fractions occurring at approximately 320 bp,
roughly the size of two nucleosomes (Figure 4c). Indeed,
the proportion of DNA fragments greater than 300 bp is
3.8-fold higher in methylated fragments (13.3%) than in
unmethylated fragments (3.5%; Figure 4c). Conversely,
the proportion of short (<100 bp) ccf DNA fragments is
increased in regulatory regions including promoters
(4.8%) and CpG islands (8.2%) relative to the entire gen-
ome (2.2%; Additional file 1: Figure S22). Overall, these
data link DNA methylation and potentially other epigen-
etic marks to fragment length in ccf DNA.
Non-invasive prenatal aneuploidy detection is linked
to the fraction of fetal (placental) DNA in the sample
[42-45]. We hypothesized that the global hypomethyla-
tion of the placenta may allow enrichment for fetal
DNA. We isolated ccf DNA from the plasma of an inde-
pendent set of 12 pregnant donors, three of which weren-pregnant ccf DNA. (a) Fragment size of ccf DNA as measured by
at approximately 92 to 98 bp is an artifact of adapter trimming prior
large fragments (>200 bp) relative to methylated cytosines in small
bar represents a single sample. (c) Size distribution of unmethylated
presents an individual sample fraction. Inset plot provides a quantified
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21, and measured each sample with and without enrich-
ing for unmethylated DNA. Data from a subset of PHDs
showed that enriching for unmethylated DNA resulted
in a 3.99-fold (range, 2.9- to 5.9-fold) increase in
chromosome 21 z-scores in trisomy 21 samples relative
to the same samples without enrichment; one sample
from a euploid pregnancy showed a similar level of en-
richment (Additional file 1: Figure S23). Overall, while
the sample size is small, these data suggest that placenta
hypomethylation may be leveraged to increase the effect-
ive fetal fraction in pregnant ccf DNA samples.
Discussion
We created whole genome methylome maps for a total
of 27 samples from four distinct sample types, enabling
a comprehensive characterization of the methylome of
ccf DNA from pregnant plasma and each of its primary
cellular and non-cellular contributors. We identified a
total of 152 DMRs when comparing non-pregnant ccf
DNA to DNA isolated from buffy coat, thought to be
the primary cellular contributor to this nucleic acid pool.
While the DNA methylation patterns are similar (Pear-
son correlation = 0.954), the differences identified are
consistent with additional minority contributors to non-
pregnant ccf DNA. Further studies are required to deter-
mine the identity of additional contributors, but sources
may include organ systems with extensive bloodstream
contact including the kidneys, liver, or endothelium. We
also identified 51,259 DMRs when comparing placenta
to non-pregnant ccf DNA. Previous studies have identi-
fied placenta specific methylated sites within subsets of
the genome [18-20]. In each of these studies, the authors
have used a model system consisting of placenta and
buffy coat/PBMC to identify these DMRs. Results from
our study show a much greater number of differentially
methylated regions when comparing buffy coat to pla-
centa (105,874), suggesting a higher false positive rate
when using this genomic DNA model system alone.
While we identified genome-wide placental hyper-
methylated regions consistent with previous studies, we
have also leveraged the global hypomethylation patterns
in the the placenta for an initial proof of concept study
for fetal enrichment. Specifically, we evaluated the
principle of global hypomethylation as a method of
enriching for fetal DNA in a set of 12 ccf DNA samples
from pregnant female donors, three of which carried a
fetus with trisomy 21 (T21). Using a z-score cutoff of
three to suggest an overrepresentation of chromosome
21 in the samples enriched for unmethylated DNA, all
three of the T21 samples were detected. In addition,
there was one euploid sample which exhibited similar
enrichment and thus would be categorized as a false
positive using this classification criteria. While these dataare promising as an early proof of concept, further work
is needed to evaluate the robust performance of DNA
hypomethylation as a method for fetal DNA enrichment
in ccf DNA derived from the plasma of pregnant donors.
This study was designed to evaluate the proposed
major contributors of nucleic acids into the plasma of a
pregnant individual. As part of this design, independent,
unpaired samples were used for each of the discovery
and confirmatory processes. While using a paired study
design would have improved the continuity of the com-
parisons between methods, we hypothesized that this
unpaired study design would produce a higher likelihood
that the results are reproducible across a larger sample
set. Furthermore, since the methylation patterns in ccf
DNA from pregnant plasma were consistent with the re-
gions we identified in placenta samples despite differ-
ences in gestational age between these sample types
(Additional file 3: Table S1), the identified differences
are likely stable during early gestation; however, since all
ccf DNA and placenta samples were obtained from do-
nors at less than 25 weeks, we cannot rule out that
changes in DNA methylation occur within these regions
during late gestation.
While evaluating the genomic distribution of DMRs,
we unexpectedly observed large regions of placental hy-
pomethylation. These data are reinforced by a recent
study which identified a similar pattern in a single pla-
centa sample using low coverage WGBS [35]. Further
characterization of these regions indicated that they
were present in regions with low CpG and gene density.
Regions with these characteristics are often located
within heterochromatinized domains, pointing to a re-
duction in the formation or re-distribution of hetero-
chromatin in the developing placenta. This is supported
by the observed decrease in CpG methylation in the pla-
centa within regions containing the H3K9me3 mark in
PBMC (Additional file 1: Figure S15). The identified
PHDs showed characteristics consistent with the par-
tially methylated domains and/or global hypomethyla-
tion previously described in cancer subtypes [24,30,33].
Commonalities between the placenta and tumors have
been previously described and include an increased pro-
liferation rate, the ability to migrate, and invasive poten-
tial [46]. These data indicate that the parallels between
cancer and the placenta extend to their epigenomes and
may provide an experimental opportunity for elucidating
the molecular source of these similarities. In addition,
such similarities suggest that lessons learned from this
study may be directly applicable to non-invasive tumor
detection and monitoring.
Conclusions
This project enabled the generation of methylome maps
for each sample type at single base resolution, identified
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length of ccf DNA, provided comprehensive lists of dif-
ferentially methylated regions (DMRs) between sample
groups, and uncovered the presence of megabase-size
PHDs. Taken together, this study advances the biological
understanding of ccf DNA and placenta. Furthermore it
delivers the ccf DNA methylome at single base reso-
lution as a reference for future non-invasive diagnostic
studies.
Methods
Blood processing and DNA extraction
Plasma samples were collected under two separate Investi-
gational Review Board (IRB) approved clinical protocols
(BioMed IRB 301–01 and Western IRB 20090444). Buffy
coat and placenta tissue was collected from consented
subjects under a Western IRB approved protocol
(20111833, study #1128724) and in accordance with the
FDA Guidance on Informed Consent for in vitro Diagnos-
tic Device Studies Using Leftover Human Specimens that
are Not Individually Identifiable (25 April 2006). All sub-
jects provided written informed consent prior to undergo-
ing any study-related procedures. All information was
anonymized prior to processing. Blood was processed and
DNA extracted as previously described [42,44,47]. Further
information about all samples subjected to WGBS is sup-
plied in Additional file 3: Table S1.
Library preparation of ccf DNA
For libraries created from ccf DNA, DNA was subjected
to end repair, mono-adenylation, and ligation as previ-
ously described [43,47]. Ccf DNA exists as small frag-
ments and thus no size selection is required prior to
sequencing; therefore, the length of each library insert
reflects of native DNA fragment length. Ligated products
were treated with sodium bisulfite (EpiTect; Qiagen)
using a cycling incubation of 95°C for 5 min, 60°C for
25 min, 95°C for 5 min, 60°C for 85 min, 95°C for 5 min,
and 60°C for 175 min followed by three cycles of 95°C
for 5 min, 60°C for 180 min. Each reaction was purified
according to the manufacturer’s instructions (Qiagen).
Converted product was amplified using Pfu Turbo Cx
Hotstart DNA polymerase (Agilent) and the TruSeq
primer cocktail (Illumina) using the following cycling
parameters: 95°C for 5 min; 98°C for 30 s; 14 cycles of
98°C for 10 s, 65°C for 30 s, 72°C for 30 s; and 95°C for
5 min.
Library preparation of genomic DNA
For libraries created from buffy coat or placenta tissue,
genomic DNA (10 μg) was fragmented by sonication
and column purified (Qiagen). Three ligated products
were prepared from each sample (2.5 μg each) by per-
forming end repair, mono-adenylation, and adapterligation according to the manufacturer’s protocol (TruSeq;
Illumina). Bead-based purification (AMPure XP; Beckman
Coulter) was performed after the end repair and ligation
processes. Ligated products were pooled and two distinct
bisulfite conversion reactions were performed as described
above. Eluted products from each sample were pooled and
concentrated using a column-based method (Qiagen).
Finally, 40% of each converted sample was amplified as
described above. PCR products were purified using
magnetic beads (AMPure XP; Beckman Coulter).
Methyl-CpG immunoprecipitation (MCIp) library
preparation
Ccf DNA was isolated from the plasma of either two
non-pregnant female donors or 12 pregnant female do-
nors and subjected to methyl-CpG immunoprecipitation
according to the manufacturer’s instructions (EpiMark;
New England Biolabs). Briefly, DNA was incubated with
the MBD-Fc protein in the presence of 150 mM NaCl.
DNA which did not bind to the protein was collected
and characterized as the unmethylated fraction. The
protein-DNA complex was washed three times with
150 mM NaCl and DNA was eluted by heating to 65°C
for 15 min. Resultant unmethylated and methylated frac-
tions from each donor sample were subjected to library
preparation using a modified version of the manufac-
turer’s protocol. Due to low input amounts, adapter
ligation was performed using a diluted adapter oligo-
nucleotide (1:10 for unmethylated; 1:100 for methylated).
Resultant ligated ccf DNA was amplified using TruSeq
PCR Master Mix and TruSeq primer cocktail (Illumina)
using the following cycling parameters: 98°C for 30 s;
10 cycles of 98°C for 10 s, 65°C for 30 s, 72°C for 30 s;
and 72°C for 5 min.
Massively parallel sequencing
Library quantification and flowcell clustering were per-
formed as previously described [42,44,47]. Paired end se-
quencing was performed for 100 cycles for all whole
genome bisulfite samples and 36 cycles for all MCIp-seq
samples.
Whole genome bisulfite sequencing analysis
Libraries prepared from Phi-X were sequenced upon
each flowcell to ensure accurate basecalling. All methyla-
tion analysis was performed using v0.9.0 of the Illumina
bisulfite sequencing analysis program. Bismark v.06.3
[48] was utilized to align each sequenced read to a bisul-
fite converted human genome (hg19) using Bowtie
v.0.12.7 [49] and simultaneously perform cytosine methy-
lation calls. Prior to alignment, each read was trimmed to
remove contaminating adaptor sequences. Each trimmed
sequence read was then aligned to each of four bisulfite
converted genomes, each derived from the conversion of
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ment was determined by the single best alignment score
to one genome. Methylation was subsequently called for
each covered cytosine and summary statistics calculated
using the Bismark methylation_extractor script.
MCIp sequencing analysis
Data were aligned to the February 2009 build of the hu-
man genome (hg19) allowing for only perfect matches
within the seed sequence using Bowtie. All paired reads
with an insert size greater than 500 bp (0.1% to 0.4% of
all sequencing reads) or with discordant chromosome
mapping results were discarded prior to analysis. Size
was calculated as the distance between the start site of
each of the two paired end reads.
Post-analysis processing
Post-analysis processing was performed using custom
scripts in an R or perl programming environment.
Under the assumption that strand specific methylation is
uncommon in ccf DNA, methylation calls mapped to
the reverse strand were converted to their corresponding
forward strand positions and methylation levels recalcu-
lated prior to all analyses. The location of each genomic
region was obtained from the hg19 build of the UCSC
genome browser. Length of each read was calculated by
subtracting the distance of the start position of each
paired read. The ENCODE data for the four histone tail
modifications in PBMC samples was downloaded as nar-
rowPeak files from the UCSC genome ENCODE site.
DMR identification
The mean and standard deviation were calculated for
each covered CpG site for each sample type. A t-statistic
was then calculated for each CpG site for all compari-
sons. All sites with a t-statistic with an absolute value
less than 5 were removed. CpG sites were grouped if
there was less than 300 bp between them after t-statistic
filtering. A region was then considered a DMR if there
were nine or more CpG sites present.
EpiTYPER (MassARRAY) analysis
EpiTYPER analysis was performed as previously de-
scribed [50]. Samples used for EpiTYPER analysis were
distinct from those used for WGBS. To confirm WGBS
methylation levels, an independent set of eight placenta
villi samples and eight maternal buffy coat samples were
used. An additional independent set of six placenta villi
samples and eight non-pregnant ccf DNA samples were
used for DMR validation. Regions were selected for
DMR validation using EpiTYPER if they were located on
chromosomes which most commonly exhibit trisomies
(chromosomes 13, 18, and 21) and if they werehypermethylated in placenta tissue relative to ccf DNA
from non-pregnant plasma.
Gene expression analysis
RNA was extracted from an independent set of eight
placenta villi samples according to manufacturer’s proto-
col (Qiagen) and hybridized to Affymetrix Human Exon
1.0 ST microarrays. All raw data files (.CEL) were sub-
jected to rma-sketch normalization using Affymetrix
Power Tools scripts. Results were subsequently filtered to
remove all transcripts which were not included as part of
the main array design (4,219) and transcripts without a
defined gene (329), leaving a final set of 17,463 genes. All
genes without a defined TSS as part of the refseq or
Ensembl gene lists or those not located on autosomes
were discarded, leaving a final set of 16,231 genes. These
genes were subsequently tiered into the high (5,410), low
(5,411), and intermediate (5,410) expressing genes.
MCIp trisomy evaluation
Ccf DNA was extracted from two aliquots of plasma
(4 mL each) collected from 12 pregnant female donors,
three of which were carrying a fetus affected with trisomy
21. The ccf DNA from each sample was then pooled to
minimize any collection bias and subsequently separated
into two aliquots. Aliquots were then either left untreated
or subjected to MCIp to enrich for unmethylated DNA.
Sequencing libraries were prepared and sequenced as de-
scribed above. All data which aligned within a subset of
the identified placenta hypomethylated regions were used
for downstream analysis. The median and median abso-
lute deviation (MAD) were calculated using data from
known euploid samples only for both unenriched and
enriched samples independently. Depending on the group
(unenriched vs. enriched), chromosome 21 z-scores were
calculated using a robust method as follows: Z = (Chr 21
Fractionsample-Chr 21 FractionMedian)/Chr 21 FractionMAD.
Data availability
All WGBS data from this study have been deposited in
the dbGaP database and are available under accession
number phs000846.
Additional files
Additional file 1: Additional Supplementary Information. This file
contains all supplementary figures referred to within the text of the
manuscript.
Additional file 2: Figure S2. Circos plot of all sample types. All
autosomes are plotted and labeled along the perimeter with each
concentric circle representing the mean methylation for each sample
type. From the outside of the concentric circles working inward,
methylation levels are shown for placenta (red), pregnant ccf DNA (blue),
non-pregnant ccf DNA (green), and buffy coat (orange). The height of
Jensen et al. Genome Biology  (2015) 16:78 Page 10 of 11each histogram within each concentric circcle represents the mean
methylation level for CpG sites within non-overlapping, 1 MB genomic bins.
Additional file 3: Table S1. Additional information regarding each
sample subjected to WGBS.
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